Share-based Payment Arrangement, Expense in USD of Terns Pharmaceuticals, Inc. from Q1 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Terns Pharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2020 to Q3 2025.
  • Terns Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2025 was $3.34M, a 19.6% decline year-over-year.
  • Terns Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2025 was $13.1M, a 17.8% decline year-over-year.
  • Terns Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $15.6M, a 38.8% decline from 2023.
  • Terns Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $25.5M, a 137% increase from 2022.
  • Terns Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $10.8M, a 32.2% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)

Terns Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $13.1M $3.34M -$817K -19.6% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-10
Q2 2025 $13.9M $3.03M -$1.39M -31.5% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-05
Q1 2025 $15.3M $3.68M -$351K -8.71% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-08
Q4 2024 $15.6M $3.02M -$261K -7.95% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-20
Q3 2024 $15.9M $4.16M -$9.93M -70.5% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-10
Q2 2024 $25.8M $4.42M +$187K +4.42% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-05
Q1 2024 $25.6M $4.03M +$90K +2.29% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-08
Q4 2023 $25.5M $3.28M +$595K +22.1% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-20
Q3 2023 $24.9M $14.1M +$11.4M +424% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $13.5M $4.23M +$1.58M +59.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 $12M $3.94M +$1.19M +43.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 $10.8M $2.69M +$137K +5.37% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 $10.6M $2.69M +$831K +44.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $9.8M $2.65M +$742K +38.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $9.06M $2.74M +$912K +49.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $8.15M $2.55M +$1.76M +224% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-27
Q3 2021 $6.38M $1.86M +$1.34M +262% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $5.04M $1.91M +$1.72M +905% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $3.32M $1.83M +$1.63M +807% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $1.69M $786K Oct 1, 2020 Dec 31, 2020 10-K 2022-03-07
Q3 2020 $513K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $190K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 $202K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14

Terns Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $15.6M -$9.91M -38.8% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-20
2023 $25.5M +$14.8M +137% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-20
2022 $10.8M +$2.62M +32.2% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-14
2021 $8.15M +$6.46M +382% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-27
2020 $1.69M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.